Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 3, 2020

View Archived Issues

SAB initiates phase I trial of SAB-176 for treatment of seasonal influenza

Fish model identifies druggable osteoporosis targets

Tryptophan metabolites keep gut barrier strong

First mouse-adapted strain of SARS-CoV-2

Novel radioimmunotherapeutic shows promise for clear cell renal cell carcinoma

Phenex-FXR patents new oxysterol receptor inverse agonists

Theralase updates on phase II study of TLD-1433 plus TLC-3200 in non-muscle-invasive bladder cancer

Vertex Pharmaceuticals synthesizes new analgesic drugs

Calithera Biosciences identifies arginase inhibitors

Accro Bioscience patent describes necrosis inhibitors

WARF presents new antifungal compounds

Phase Ib efficacy assessment of ETC-159 begins in patients with cancer

Phase III trial approved for RHB-204 for nontuberculous mycobacteria infections

Recruitment underway for trial of Roche's RO-7248824 in Angelman syndrome

First-in-human trial of BNT-411 underway in solid tumor and lung cancer patients

Endothelial-specific form of type 18 collagen COL-18N is a marker of hemophilic arthropathy

Primary endpoint met with IMU-838 in phase II relapsing-remitting multiple sclerosis trial

Innovent Biologics commences phase I trial of IBI-322 in advanced cancer

FDA approves Epidiolex for seizures in tuberous sclerosis complex

MorphoSys receives FDA approval for Monjuvi for diffuse large B-cell lymphoma

Data presented for OGA inhibitor LY-3372689 in healthy subjects

Cosentyx approved in the E.U. for pediatric psoriasis

Rozlytrek approved in E.U. for NTRK fusion solid tumors and for ROS1-positive advanced NSCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...